Navigation Links
Dr. David Hangauer, Chief Scientific Officer and Co-Founder, commits his career to Kinex Pharmaceuticals
Date:9/12/2013

culty position and devote the rest of my career to the company.  The 24 years that I have taught chemistry and carried out basic research at the University have been very gratifying, but bringing life changing drugs to thousands of patients is even more rewarding.  Kinex was initially formed from the basic research in my academic lab, and it is important to me, along with my dedicated and talented colleagues, to continue to help Kinex develop novel clinical solutions.  I am very much looking forward to focusing solely on improving outcomes and, therefore, lives."

Dr. Johnson Lau, CEO and Chairman of Kinex, added, "Dr. Hangauer is a phenomenal and dedicated drug discovery scientist and a humble and honorable person and I am delighted to have worked by his side for the last 10 years. Kinex was founded based on his research and he has continued to help Kinex to evolve and grow since its inception.  His discovery and development successes with KX01 and KX02 have allowed Kinex to forge important strategic relationships with Hanmi Pharmaceutical, PharmaEssentia, and Xiangxue Pharmaceuticals, which allows us to further our global development strategy.  His scientific leadership is the key to the remarkable productivity of the Kinex research team. He is a great team player with an unmatched work ethic and I am honored to have worked with him over the last decade. Dave's full time commitment to Kinex is wonderful news for our collaborative partners, shareholders and most importantly, patients.  Kinex is proud to have David as our CSO."

About Kinex:

Founded in 2004, Kinex is led by a strong, experienced Management Team and Board of Directors with a track record of achieving value-creating milestones and cumulative experience of over 250 years in both the pharmaceutical and biotechnology industries. This includes the filing of more than 11 NDAs and 20 INDs with the Food and Drug
'/>"/>

SOURCE Kinex Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. David F. Harty Joins Systech International as Vice President
2. Dr. David Brailer and Stephen Dubner Keynotes for NYeC 2012 Digital Health Conference
3. WebMD Taps David C. Marek to Assume Consumer Leadership Role
4. arGEN-X Appoints Dr. David L. Lacey to its Supervisory Board
5. Alliqua Names David Johnson Executive Chairman of Aquamed Technologies and Member of Alliqua Board of Directors
6. David Norton Appointed to TB Alliances Board of Directors
7. Aquavit Pharmaceuticals Inc. Appoints David Shafer, MD., FACS., New Chief Medical Technology Officer
8. Dynamic Healthcare Services Announces David Erb as Director of Sales
9. Kinex Pharmaceuticals Chief Scientific Officer, Dr. David Hangauer, named the American Cancer Societys 2013 Honoree for its Cuisine for a Cure event
10. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
11. MetaStat Appoints David Epstein, Ph.D. as Advisor to Lead Drug Discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 According to a ... Devices Market (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) ... Forecast, 2013-2019" the global endoscopy devices market was valued ... to grow at a CAGR of 6.8% from 2013 ... 36.9 billion in 2019. Browse the full ...
(Date:7/10/2014)... 11, 2014  Major advances in radiation therapy ... being highlighted in a three-day Oncology Summit taking ... July, 2014.  Renowned national and international cancer experts from ... and exchange knowledge on modern technologies making treatment ... The Summit will address a ...
(Date:7/10/2014)... SAN DIEGO , July 10, 2014  RESMED INC. ... report its fourth quarter and fiscal year ended June 30, ... York Stock Exchange market close. A press release with ResMed,s ... and the company will host a webcast to discuss operating ... scheduled to begin at 1:30 p.m. US Pacific Time and ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... , , STAMFORD, Conn. , Feb. ... subsidiary of Speedus Corp. (Nasdaq: SPDE ), was jointly named ... February 11th—the 163rd birthday of renowned inventor Thomas Alva Edison—at a ... City . Edison created many of the products and technologies taken ...
... , , REDWOOD CITY, Calif. , Feb. ... collaborations in pharmaceutical manufacturing with Dishman Pharmaceuticals and Chemicals ... American Pacific Corporation. These agreements expand the application of ... pharmaceutical products. , Under the new agreements, Codexis ...
Cached Medicine Technology:Zargis Cardioscan Jointly Named as Finalist in 2010 Edison Best New Product Awards 2Zargis Cardioscan Jointly Named as Finalist in 2010 Edison Best New Product Awards 3Codexis Expands Pharmaceutical Manufacturing Partnerships 2Codexis Expands Pharmaceutical Manufacturing Partnerships 3
(Date:7/12/2014)... Pittsburgh, PA (PRWEB) July 12, 2014 "The ... so it’s uncomfortable and painful to wear shoes," said an ... a special sock that prevents this from happening. , He ... an effective way to prevent the second and big toes ... more endurance while wearing shoes. Ergonomic and easy to use, ...
(Date:7/12/2014)... “After my mom’s stroke, she loss the use of ... the use of his left side. Eating became a difficult task ... people like them enjoy eating again,” said an inventor, from Fayetteville, ... CAROL HALL PLATE (P C H PLATE). , The PATRICIA CAROL ... to eat for individuals who suffer from stroke, experience tremors or ...
(Date:7/12/2014)... New York, New York (PRWEB) July 12, 2014 ... ) continue to move forward in U.S. courts, Bernstein ... that ties elevated metal ion levels to the failure ... the July 2nd issue of The Journal of Bone ... had received unilateral Articular Surface Replacement prostheses at ...
(Date:7/12/2014)... Beverly Hills, CA (PRWEB) July 12, 2014 ... reason why are bodies can readily absorb the nutrients in ... into tiny particles that are small enough to be absorbed ... the DZ10 team, a lack of enzymes in regular food ... DZ10 is a product that was started by Michelle DelPresto, ...
(Date:7/12/2014)... Albany, NY (PRWEB) July 12, 2014 ... to 2020 - New and Late-Stage Four-Factor PCCs ... in-depth analysis of the critical care market in ... and Canada. The report provides an estimation of ... to 2020. It covers critical care indications that ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6
... French . , Recent animal studies have ... used to treat diarrhea and other gastrointestinal disorders ... diseases. Scientists, however, had a variety of theories to ... such similar effects on three unrelated neurodegenerative disorders. , ...
... AMERIGROUP Corporation (NYSE: AGP ) today announced that ... Conference on January 14 in San Francisco.A live broadcast of ... p.m. Eastern Time, can be accessed on AMERIGROUP,s Web site, ... be available for 30 days, and can be accessed at ...
... Jan. 6, Halo Pharmaceutical, Inc., a privately ... completion of its acquisition of the Whippany-NJ Manufacturing ... ABT ). At over 200,000 square feet, ... including an impressive array of formulation services, operations ...
... remain stableWASHINGTON, Jan. 6 Karen Ignagni, President and CEO ... data released by CMS today showing that health spending in ... decade at 6.1 percent in 2007. According to the ... 2007, the same rate as in 2006, but much lower ...
... UCSF has received a $7.5 million grant from the Bill & ... to help address Africa,s urgent need for healthcare workers. , ... ... San Francisco has received a $7.5 million grant from the Bill ...
... With 30 million drivers in the US aged 65 ... they can no longer drive safely and decide that it,s ... that a decrease in vision function is a key factor ... and Driving Study (SEEDS) ( http://www.iovs.org/cgi/content/full/50/1/107 ), conducted by researchers ...
Cached Medicine News:Health News:Old gastrointestinal drug slows aging, McGill researchers say 2Health News:Halo Pharmaceutical, Inc. Acquires Whippany Manufacturing Facility from Abbott 2Health News:Halo Pharmaceutical, Inc. Acquires Whippany Manufacturing Facility from Abbott 3Health News:AHIP Statement on National Health Expenditure Data 2Health News:UCSF and Muhimbili University Launch Initiative to Strengthen Tanzanian Health Workforce 2Health News:UCSF and Muhimbili University Launch Initiative to Strengthen Tanzanian Health Workforce 3Health News:Vision problems prompt older drivers to put down the keys 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: